新冠疫苗

Time for other vaccine makers to follow Oxford/AstraZeneca’s lead

We at the university, alongside the drugmaker, felt we should not profiteer from a pandemic

The writer is vice-chancellor of the University of Oxford

Over a year ago, Oxford university scientists anticipated the potential impact of the emerging coronavirus and believed that they might be able to produce an effective vaccine. The speed with which they were able to do so was due, in part, to 20 years’ worth of work on infectious disease with colleagues in Africa and Asia. Given their experience in the developing world, they knew just how devastating a global pandemic would be in poor countries and what a risk this would pose to the rest of the world.

Many of their worst fears are coming true. Globally, we may have not yet reached the peak of the pandemic; the death toll could exceed 9m by September. The heart-rending scenes from India showing the devastating consequences of Covid-19 pose a challenge to the conscience of the world.

您已閱讀18%(848字),剩餘82%(3831字)包含更多重要資訊,訂閱以繼續探索完整內容,並享受更多專屬服務。
版權聲明:本文版權歸FT中文網所有,未經允許任何單位或個人不得轉載,複製或以任何其他方式使用本文全部或部分,侵權必究。
設置字型大小×
最小
較小
默認
較大
最大
分享×